TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06480500

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: i-CBT (Internet-based Cognitive Behavioural Therapy)
Description: Each week for 13 weeks, participants will watch an online module that last approximately 45-50 mins each, with homework at the end of each module. Homework is submitted and reviewed by a therapist, who will provide personalized feedback before progression to the next module.
Study: NCT05590325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Single dose of the DTG-DT in two sequential cohorts and multiple-doses of the DTG-DT or DTG-ODF in a two cohorts.~Qualitative Acceptability will be collected from mothers and health workers in structured discussion guides.
Study: NCT05903001

Intervention type: DIAGNOSTIC_TEST
Intervention: 6-minute walking distance
Description: The maximum walking distance achieved in 6 minutes

Intervention type: DIAGNOSTIC_TEST
Intervention: 6-minute walking distance
Description: The maximum walking distance achieved in 6 minutes

Intervention type: DIAGNOSTIC_TEST
Intervention: 60 seconds sit-to-stand test
Description: number of repetitions achieved in sitting down and standing up in 60 seconds

Intervention type: DIAGNOSTIC_TEST
Intervention: 60 seconds sit-to-stand test
Description: number of repetitions achieved in sitting down and standing up in 60 seconds

Intervention type: DIAGNOSTIC_TEST
Intervention: 60 seconds sit-to-stand test
Description: number of repetitions achieved in sitting down and standing up in 60 seconds

Intervention type: DIAGNOSTIC_TEST
Intervention: 60 seconds sit-to-stand test
Description: number of repetitions achieved in sitting down and standing up in 60 seconds

Intervention type: DIAGNOSTIC_TEST
Intervention: Electromyography
Description: electromyography of the muscles of respiration via superficial electrodes

Intervention type: DIAGNOSTIC_TEST
Intervention: Electromyography
Description: electromyography of the muscles of respiration via superficial electrodes

Intervention type: DIAGNOSTIC_TEST
Intervention: Electromyography
Description: electromyography of the muscles of respiration via superficial electrodes

Intervention type: DIAGNOSTIC_TEST
Intervention: Electromyography
Description: electromyography of the muscles of respiration via superficial electrodes
Study: NCT06464237

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mio-App
Description: The Mio-App aims to increase metacognitive knowledge, teaches mnemonic skills, trains the working memory capacity and motor skills to reduce cognitive and physical long-term sequelae after cancer during adolescence.
Study: NCT06337630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX038 + Tuvusertib
Description: Dose escalation will be conducted on the grid defined by the 4 doses of PLX038 (800 mg/m², 1000 mg/m², 1300 mg/m² and 1700 mg/m² IV every 21 days D1=D22) and 3 doses of Tuvusertib (90 mg, 130 mg and 180 mg QD for 10 days from D3, D3-12). Premedication with anti-emetic agents is not required prior to the initial infusion, but may be used for an individual patient, as needed.~All included patients will receive PLX038 + Tuvusertib until progression of disease, unacceptable toxicity, patient withdrawal of consent, investigator decision, lost to follow-up, death, patient non-compliance, or study termination by Sponsor.
Study: NCT06538324

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: Dietary Supplement: Omega-3 In the marine Omega-3 fatty acid period, the participants will receive a capsule with 250 mg of EPA per day during 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: HOSO
Description: Dietary Supplement: HOSO In the HOSO period, the participants will receive a capsule with the similar weight of HOSO per day during 6 weeks.
Study: NCT05774873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI334 D
Description: Subjects will receive IBI334 D once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI334 C
Description: Subjects will receive IBI334 C once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI334 A
Description: Subjects will receive IBI334 A once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI334 B
Description: Subjects will receive IBI334 B once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI334 F
Description: Subjects will receive IBI334 F once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI334 E
Description: Subjects will receive IBI334 C once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
Study: NCT06480500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam Hydrochloride
Description: 55 patients will receive midazolam hydrochloride, over six infusions, flexibly dosed between 0.02 mg/kg to 0.035 mg/kg.
Study: NCT05903001

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Function
Description: Measurement of lung function via body plethysmography

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Function
Description: Measurement of lung function via body plethysmography

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Function
Description: Measurement of lung function via body plethysmography

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Function
Description: Measurement of lung function via body plethysmography

Intervention type: DIAGNOSTIC_TEST
Intervention: CAT-Questionnaire
Description: COPD Assessment Test (CAT)

Intervention type: DIAGNOSTIC_TEST
Intervention: European Society of Cardiology (ESC)/ European Respiratory Society (ERS) risk group
Description: Patients with pulmonary hypertension are classified according to the ESC/ERS risk group.
Study: NCT06282588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Firmagon 80 MG Injection
Description: 80 mg, subcutaneous use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: 75 mg per square m, IV infusion
Study: NCT06282588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg per square m, IV infusion
Study: NCT04390113

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Posoleucel (ALVR105)
Description: Administered as 2-4 milliliter infusion, visually identical to placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as 2-4 milliliter infusion, visually identical to Posoleucel (ALVR105)
Study: NCT04886583

Intervention type: DEVICE
Intervention: Gabi Baby Band
Description: Every enrolled patient must wear the Gaby Baby Band on the left arm in the aim to perform data analytics after the test has been performed
Study: NCT06134739

Intervention type: OTHER
Intervention: No intervention.
Description: Observational study, no intervention.
Study: NCT04495387

Intervention type: DRUG
Intervention: Chemotherapy
Description: standard adjuvat chemotherapy for reast and colo cancer
Study: NCT05284968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cell injection
Description: All subjects will be treated with cell injection
Study: NCT04698980

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood samples (venous and capillary at the fingertip)
Description: For each participant, the intervention will be a fingertip sample to perform the STANDARD G6PD test and two blood samples on EDTA to perform the reference test
Study: NCT04993326

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: emPOWERed To Change Program
Description: Online Diabetes Self-Management Education and Support along with COVID-19 prevention and protection (vaccination) education and resource information
Study: NCT04246970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Supervised training program of 8-weeks and a frequency of 2 days/week. It includes interval aerobic exercise (5 cycles of 2 minutes at 70 percentage of Watts or heart rate of cardiopulmonary exercise testing (CEPT) and 3 minutes of active rest at 40 percentage; peripheral muscle training and balance exercises in a circuit of 10 phases, 10 to 15 repetitions, from 1 to 3 sets (the participants will work at moderate intensity, no more than 5-6/10 on the modified Borg scale); Inspiratory Muscle Training (IMT) through a threshold loading device \[2 sessions / day, 3 sets of 15 repetitions, at 60-70 percentage of the maximum inspiratory pressure (cmH2O)\]; ventilatory reeducation by an incentive inspirator based on the vital capacity evaluated in the initial spirometry. Both the aerobic modality and the resistance training, will increase the intensity of work (HR, Watts, Kg or cmH2O) between 2-5 percentage every 2 weeks complying with the principle of training overload.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Supervised training program of 8-weeks and a frequency of 2 days/week. It includes interval aerobic exercise (5 cycles of 2 minutes at 70 percentage of Watts or heart rate of cardiopulmonary exercise testing (CEPT) and 3 minutes of active rest at 40 percentage; peripheral muscle training and balance exercises in a circuit of 10 phases, 10 to 15 repetitions, from 1 to 3 sets (the participants will work at moderate intensity, no more than 5-6/10 on the modified Borg scale); Inspiratory Muscle Training (IMT) through a threshold loading device \[2 sessions / day, 3 sets of 15 repetitions, at 60-70 percentage of the maximum inspiratory pressure (cmH2O)\]; ventilatory reeducation by an incentive inspirator based on the vital capacity evaluated in the initial spirometry. Both the aerobic modality and the resistance training, will increase the intensity of work (HR, Watts, Kg or cmH2O) between 2-5 percentage every 2 weeks complying with the principle of training overload.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation and posttransplant training program
Description: Prehabilitation will be followed by a posttransplant training program. In this, the patient will perform supervised exercise (IIa interval aerobic exercise and resistance training) 2 days / week, and a physical exercise program at home until completing a total of 5 sessions / week in the aerobic modality. In the unsupervised phase (IIb), the patient will continue with the learned physical exercise program, but without supervision, 5 sessions / week (including a minimum of 2 non-consecutive sessions to perform resistance training).
Study: NCT06526858

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HyperQureTM Renal Denervation (RDN) System:
Description: The HyperQure RDN System consists of a Generator that generates RF energy and a Laparoscopic Instrument that delivers the RF energy generated by the generator to the treatment area. Through a extravascular(laparoscopic) approach, the renal artery is accessed through the retroperitoneum, which is the closest path to the renal artery. After wrapping 360 degrees of renal artery, RDN is performed as per the preset parameters of 50 degrees and 70 seconds.~The target blood vessels will be planned by CTA before the procedure, and the proximal and distal areas of the right and left main renal artery are treated once at a distance of at least 3 mm respectively, and RDN will be also performed on the branch or accessory vessels confirmed to be suitable for the procedure by CTA.
Study: NCT05655793

Intervention type: DIAGNOSTIC_TEST
Intervention: Tear Fluid collection (Schirmer's strip)
Description: Tear fluid will be collected non-invasively form all participants with the use of Schirmer's strips, which is a small paper strip placed in the lower eye lid for a maximum of 5 minutes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Tear Fluid collection (Schirmer's strip)
Description: Tear fluid will be collected non-invasively form all participants with the use of Schirmer's strips, which is a small paper strip placed in the lower eye lid for a maximum of 5 minutes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Retinal imaging
Description: The retina from all participants will be visualised with the use of a standard (Clarus 700 Zeiss), ultra-wide field (Optos), and cross-sectional (Optical Coherence Tomography) retinal images.

Intervention type: DIAGNOSTIC_TEST
Intervention: Retinal imaging
Description: The retina from all participants will be visualised with the use of a standard (Clarus 700 Zeiss), ultra-wide field (Optos), and cross-sectional (Optical Coherence Tomography) retinal images.
Study: NCT06528223

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: biopsy or operation
Description: To obtain a biopsy pathology or surgical pathology according to the clinical process of PDAC.
Study: NCT05188846

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SDF
Description: 1. Group 1: cleaning the occlusal surface to be treated with toothbrush. Decayed tissue from the affected teeth will not be removed for the SDF group.~Clinical procedure for SDF application: it will apply according to the SDF manufacturer Instructions as follows:(1) the surrounding gingival tissues and lips will be protected with petroleum jelly to avoid staining and irritation,(2) the affected tooth will be isolated and keep dry with cotton rolls and saliva ejectors, (3) one drop of SDF (SDI RIVA STAR ), will be placed into a disposable dish, (4) SDF will be applied with a micro-sponge directly to the affected tooth surface(s), (5) allowed to soak in for 2 min, then air-dried. Then will be followed by the Potassium iodide (KI) liquid to decrease discoloration caused by SDF. The KI liquid will be reapplied until no more white perception observed to form.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SDF + ART (SMART technique )
Description: 2. Group 2: SDF+ART clinical procedure: (1)cleaning the occlusal surface to be treated with toothbrush.,(2) carious dentin will be removed using a small excavator (Spoon excavator ),(3) the cavity will be cleaned and dried, (4)cavity walls and floor will be conditioned for 10s, then washed and dried, (5) SDF will be applied as mentioned above followed by cavity restoration using resin-reinforced glass ionomer restorative material (SDI RIVA ).
Study: NCT02202473

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine+Oxymatrine Capsules
Study: NCT05631795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Film coated tablet for oral use. Participants will be treated with 300 mg of alpelisib once daily starting on Cycle 1 Day 1
Study: NCT06255899

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Program on Injury Prevention
Description: The didactic component of the injury prevention education program includes information on prevalence of injuries in female athletes, biomechanical risk factors for injury, and effectiveness of injury prevention programs (IPP) for mitigation of injury risk. Examples of different activities from the IPP, including proper and improper movement strategies will be provided. Athletes will be instructed as a group on how to properly perform of each activity of the IPP, and will be given an opportunity to practice. Athletes, coaches, and staff will be provided with links to written instructions and videos of proper performance for each activity. The IPP will be performed at least 3 times/week prior to practice. Coaches, staff, and athletes will be encouraged to provide supervision and feedback on performance of the IPP throughout the season.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Program on Injury Prevention
Description: The didactic component of the injury prevention education program includes information on prevalence of injuries in female athletes, biomechanical risk factors for injury, and effectiveness of injury prevention programs (IPP) for mitigation of injury risk. Examples of different activities from the IPP, including proper and improper movement strategies will be provided. Athletes will be instructed as a group on how to properly perform of each activity of the IPP, and will be given an opportunity to practice. Athletes, coaches, and staff will be provided with links to written instructions and videos of proper performance for each activity. The IPP will be performed at least 3 times/week prior to practice. Coaches, staff, and athletes will be encouraged to provide supervision and feedback on performance of the IPP throughout the season.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Feedback + Education Program on Injury Prevention
Description: In addition to the education program, participants in this group will receive individualized feedback on performance of the IPP. The participant will be videotaped while performing the IPP, and movement errors and compensations will be identified to provide a basis for feedback sessions to correct movement. The session will include different forms of feedback including showing the athlete their video, identifying the error or compensation, and providing verbal, tactile, and visual feedback to correct the error or compensation. Common errors and compensations, along with verbal cues and corrections, have been identified and manualized for the study. Two additional feedback sessions will be scheduled at regular intervals during the season to provide feedback on performance throughout the season. Participants in this group will be encouraged to provide peer feedback to one another.
Study: NCT05966623

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Remote Interpretation
Description: To assess the effectiveness of the VRI system in improving communication outcomes between Deaf patients and doctors Produce a VRI model addressing the challenges faced by Deaf people that will be tested, implemented, and sustained in Bogota Colombia.
Study: NCT06063564

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREVENT
Description: PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help providers link patients to resources in their community.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wait-list Control
Description: Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool.
Study: NCT05631795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Injection for intramuscular administration. Participants will be treated with fulvestrant 500 mg on Cycle 1 Day 1 and Day 15, and Day 1 of every cycle thereafter in a 28-day cycle.
Study: NCT05531396

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Agility Training
Description: Participants will receive 60 minutes of exercise, twice a week, for a total of 8 weeks, and training will be conducted by a well-trained physical therapist. The intervention will comprise a 5-minute warm-up, 45 minutes of main exercise, and a 10-minute cool-down period, for a total of 60 minutes each session. During the warm-up and cool-down, participants will do static and dynamic whole-body stretching exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Participants in the control group will receive health educational guidelines. Guideline contents include home-based exercise program, nutrition recommendations, and fall prevention education. The home-based exercise program will emphasize how to safely and properly perform stretching and whole-body exercises.
Study: NCT06434038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Regular insulin
Description: Administered intranasally at 40 IU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Regular insulin
Description: Administered Intranasally at 80 IU

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: Placebo control
Study: NCT05469568

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circuit training followed by telerehabilitation
Description: Patients participate in an ambulatory rehabilitation program (12 weeks) and then gain access to mobile application to record their movement activities. This application will aslo inlude a library with exercise vidoes from the ambulatory program. These videos should inspire patients to do the exercises at home.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Usual care
Description: Patients have usual information about importance of regular movement activities and recommendation of proper exercises
Study: NCT05713318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HH-120 nasal spray
Description: Nasal spray daily doses of HH-120 4 times added on SOC for 6 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HH-120 nasal spray
Description: Nasal spray daily doses of HH-120 8 times added on SOC for 6 consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Nasal spray daily doses of placebo 4 times added on SOC for 6 consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Nasal spray daily doses of placebo 8 times added on SOC for 6 consecutive days.